175 related articles for article (PubMed ID: 24405856)
1. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
2. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
4. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
5. Masitinib for the treatment of mild to moderate Alzheimer's disease.
Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
[TBL] [Abstract][Full Text] [Related]
6. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of masitinib for treating systemic mastocytosis.
Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
[No Abstract] [Full Text] [Related]
9. Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Rathore K; Alexander M; Cekanova M
Transl Res; 2014 Aug; 164(2):158-68. PubMed ID: 24631063
[TBL] [Abstract][Full Text] [Related]
10. In vivo model for mastocytosis: A comparative review.
Ranieri G; Marech I; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Rizzo A; Gadaleta CD; Introna M; Patruno R; Sciorsci RL
Crit Rev Oncol Hematol; 2015 Mar; 93(3):159-69. PubMed ID: 25465741
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
12. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
13. Safety of masitinib mesylate in healthy cats.
Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
[TBL] [Abstract][Full Text] [Related]
14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
15. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
17. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
18. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]